In a report released today, Alan Carr from Needham assigned a Buy rating to Moderna (MRNA), with a price target of $94.00. The company’s shares closed last Monday at $80.80.
According to TipRanks.com, Carr is a 3-star analyst with an average return of 0.3% and a 41.8% success rate. Carr covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Phathom Pharmaceuticals, and ACADIA Pharmaceuticals.
Moderna has an analyst consensus of Strong Buy, with a price target consensus of $71.67, implying a -16.8% downside from current levels. In a report issued on May 7, Piper Sandler also reiterated a Buy rating on the stock with a $57.00 price target.
See today’s analyst top recommended stocks >>
Based on Moderna’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $8.39 million and GAAP net loss of $124 million. In comparison, last year the company earned revenue of $16.03 million and had a GAAP net loss of $133 million.
Based on the recent corporate insider activity of 80 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MRNA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Read More on MRNA: